Toward an effective peripheral visceral analgesic

Responding to the national opioid crisis

Research output: Contribution to journalShort survey

5 Citations (Scopus)

Abstract

This minireiew summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/ orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-methyl-D-aspartate, calcitonin gene-related peptide, estrogen, and adenosine A2B receptors and transient receptor potential (TRP) channels (TRPV1, TRPV4, and TRPM8). Although current evidence is based predominantly on animal models of visceral pain, early human studies also support the evidence from the basic and animal research. This augurs well for the development of nonaddictive, visceral analgesics for treatment of chronic abdominal pain, an unmet clinical need.

Original languageEnglish (US)
Pages (from-to)G637-G646
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume314
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Opioid Analgesics
Analgesics
Opioid Receptors
Abdominal Pain
Adenosine A2B Receptors
Visceral Pain
Transient Receptor Potential Channels
Buprenorphine
Peptide Receptors
Opioid Peptides
Cannabinoids
Calcitonin Gene-Related Peptide
N-Methylaspartate
Chronic Pain
Estrogens
Animal Models
Ligands
Pain
Therapeutics
morphiceptin

Keywords

  • Cannabinoid
  • Estrogen
  • Receptors
  • Transient receptor potential

ASJC Scopus subject areas

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)

Cite this

@article{8948cfd586184c9a93c5ba7b0c8facf6,
title = "Toward an effective peripheral visceral analgesic: Responding to the national opioid crisis",
abstract = "This minireiew summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/ orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-methyl-D-aspartate, calcitonin gene-related peptide, estrogen, and adenosine A2B receptors and transient receptor potential (TRP) channels (TRPV1, TRPV4, and TRPM8). Although current evidence is based predominantly on animal models of visceral pain, early human studies also support the evidence from the basic and animal research. This augurs well for the development of nonaddictive, visceral analgesics for treatment of chronic abdominal pain, an unmet clinical need.",
keywords = "Cannabinoid, Estrogen, Receptors, Transient receptor potential",
author = "Michael Camilleri",
year = "2018",
month = "6",
day = "1",
doi = "10.1152/ajpgi.00013.2018",
language = "English (US)",
volume = "314",
pages = "G637--G646",
journal = "American Journal of Physiology - Gastrointestinal and Liver Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Toward an effective peripheral visceral analgesic

T2 - Responding to the national opioid crisis

AU - Camilleri, Michael

PY - 2018/6/1

Y1 - 2018/6/1

N2 - This minireiew summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/ orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-methyl-D-aspartate, calcitonin gene-related peptide, estrogen, and adenosine A2B receptors and transient receptor potential (TRP) channels (TRPV1, TRPV4, and TRPM8). Although current evidence is based predominantly on animal models of visceral pain, early human studies also support the evidence from the basic and animal research. This augurs well for the development of nonaddictive, visceral analgesics for treatment of chronic abdominal pain, an unmet clinical need.

AB - This minireiew summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/ orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-methyl-D-aspartate, calcitonin gene-related peptide, estrogen, and adenosine A2B receptors and transient receptor potential (TRP) channels (TRPV1, TRPV4, and TRPM8). Although current evidence is based predominantly on animal models of visceral pain, early human studies also support the evidence from the basic and animal research. This augurs well for the development of nonaddictive, visceral analgesics for treatment of chronic abdominal pain, an unmet clinical need.

KW - Cannabinoid

KW - Estrogen

KW - Receptors

KW - Transient receptor potential

UR - http://www.scopus.com/inward/record.url?scp=85048218115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048218115&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00013.2018

DO - 10.1152/ajpgi.00013.2018

M3 - Short survey

VL - 314

SP - G637-G646

JO - American Journal of Physiology - Gastrointestinal and Liver Physiology

JF - American Journal of Physiology - Gastrointestinal and Liver Physiology

SN - 0193-1857

IS - 6

ER -